RESUMEN
Eight different protocols were compared for their ability to raise protection against immunodeficiency virus challenges in rhesus macaques. The most promising containment of challenge infections was achieved by intradermal DNA priming followed by recombinant fowl pox virus booster immunizations. This containment did not require neutralizing antibody and was active for a series of challenges ending with a highly virulent virus with a primary isolate envelope heterologous to the immunizing strain.
Asunto(s)
Infecciones por Lentivirus/inmunología , Infecciones por Lentivirus/prevención & control , Vacunación , Vacunas de ADN/uso terapéutico , Vacunas Virales/uso terapéutico , Animales , Anticuerpos Antivirales/sangre , Virus de la Viruela de las Aves de Corral/genética , Inyecciones Intradérmicas , Macaca , Pruebas de Neutralización , ARN Viral/sangre , Linfocitos T CitotóxicosRESUMEN
Heterologous prime/boost regimens have the potential for raising high levels of immune responses. Here we report that DNA priming followed by a recombinant modified vaccinia Ankara (rMVA) booster controlled a highly pathogenic immunodeficiency virus challenge in a rhesus macaque model. Both the DNA and rMVA components of the vaccine expressed multiple immunodeficiency virus proteins. Two DNA inoculations at 0 and 8 weeks and a single rMVA booster at 24 weeks effectively controlled an intrarectal challenge administered 7 months after the booster. These findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the acquired immune deficiency syndrome epidemic.